| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Adoption of robotic surgery: driven by market competition or a desire to improve patient care?
|
Fletcher, Sean A
|
|
2018
|
19 |
2 |
p. e66
|
artikel
|
| 2 |
Adoption of robotic surgery: driven by market competition or a desire to improve patient care? – Authors' reply
|
Aggarwal, Ajay
|
|
2018
|
19 |
2 |
p. e67
|
artikel
|
| 3 |
A new era for treatment development in HER2-positive breast cancer
|
Pivot, Xavier
|
|
2018
|
19 |
2 |
p. 160-162
|
artikel
|
| 4 |
A new option for remission induction in acute myeloid leukaemia
|
Müller-Tidow, Carsten
|
|
2018
|
19 |
2 |
p. 156-157
|
artikel
|
| 5 |
A turning point in the fight against ovarian cancer?
|
Scambia, Giovanni
|
|
2018
|
19 |
2 |
p. 154-156
|
artikel
|
| 6 |
Autoimmune hypophysitis
|
Ileana-Dumbrava, Ecaterina
|
|
2018
|
19 |
2 |
p. e123
|
artikel
|
| 7 |
Breast cancer in young women: do BRCA1 or BRCA2 mutations matter?
|
Fasching, Peter A
|
|
2018
|
19 |
2 |
p. 150-151
|
artikel
|
| 8 |
Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1–2 trial
|
O'Connor, Owen A
|
|
2018
|
19 |
2 |
p. 257-266
|
artikel
|
| 9 |
Cancer in two Renaissance families
|
Fornaciari, Gino
|
|
2018
|
19 |
2 |
p. e74
|
artikel
|
| 10 |
Cancer surveillance in northern Africa, and central and western Asia: challenges and strategies in support of developing cancer registries
|
Znaor, Ariana
|
|
2018
|
19 |
2 |
p. e85-e92
|
artikel
|
| 11 |
Cervical cancer vaccine controversy in India
|
Das, Manjulika
|
|
2018
|
19 |
2 |
p. e84
|
artikel
|
| 12 |
Considering quantity and quality of life in metastatic castration-naive prostate cancer
|
Penson, David F
|
|
2018
|
19 |
2 |
p. 153-154
|
artikel
|
| 13 |
Correction to Lancet Oncol 2017; 18: 1089–103
|
|
|
2018
|
19 |
2 |
p. e78
|
artikel
|
| 14 |
Correction to Lancet Oncol 2017; 18: e713
|
|
|
2018
|
19 |
2 |
p. e78
|
artikel
|
| 15 |
Correction to Lancet Oncol 2016; 17: e149–62
|
|
|
2018
|
19 |
2 |
p. e78
|
artikel
|
| 16 |
Daratumumab for untreated multiple myeloma
|
Stirrups, Robert
|
|
2018
|
19 |
2 |
p. e80
|
artikel
|
| 17 |
Demoralisation in palliative care
|
Townsend, Katherine
|
|
2018
|
19 |
2 |
p. 168
|
artikel
|
| 18 |
Earliest evidence of malignant breast cancer in Renaissance paintings
|
Bianucci, Raffaella
|
|
2018
|
19 |
2 |
p. 166-167
|
artikel
|
| 19 |
Generic drugs: are they the future for affordable medicine?
|
The Lancet Oncology,
|
|
2018
|
19 |
2 |
p. 149
|
artikel
|
| 20 |
Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study
|
Copson, Ellen R
|
|
2018
|
19 |
2 |
p. 169-180
|
artikel
|
| 21 |
Harnessing genomics to improve outcomes for women with cancer in India: key priorities for research
|
Sundar, Sudha
|
|
2018
|
19 |
2 |
p. e102-e112
|
artikel
|
| 22 |
Improved progression-free survival in metastatic breast cancer
|
Burki, Talha Khan
|
|
2018
|
19 |
2 |
p. e79
|
artikel
|
| 23 |
Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study
|
Kantarjian, Hagop
|
|
2018
|
19 |
2 |
p. 240-248
|
artikel
|
| 24 |
Inotuzumab ozogamicin in older patients with acute lymphoblastic leukaemia: premises and promises
|
Rizzari, Carmelo
|
|
2018
|
19 |
2 |
p. 159-160
|
artikel
|
| 25 |
In search of Mangomoments
|
Vanhaecht, Kris
|
|
2018
|
19 |
2 |
p. 165
|
artikel
|
| 26 |
International access to major US cancer database halted
|
Furlow, Bryant
|
|
2018
|
19 |
2 |
p. 164
|
artikel
|
| 27 |
Many FDA-approved cancer drugs might lack clinical benefit
|
Das, Manjulika
|
|
2018
|
19 |
2 |
p. e82
|
artikel
|
| 28 |
Negative phase 3 study of 90Y microspheres versus sorafenib in HCC
|
Garin, Etienne
|
|
2018
|
19 |
2 |
p. e70
|
artikel
|
| 29 |
Negative phase 3 study of 90Y microspheres versus sorafenib in HCC
|
Kokudo, Takashi
|
|
2018
|
19 |
2 |
p. e68
|
artikel
|
| 30 |
Negative phase 3 study of 90Y microspheres versus sorafenib in HCC
|
Llovet, Josep M
|
|
2018
|
19 |
2 |
p. e69
|
artikel
|
| 31 |
Negative phase 3 study of 90Y microspheres versus sorafenib in HCC – Authors' reply
|
Vilgrain, Valérie
|
|
2018
|
19 |
2 |
p. e71
|
artikel
|
| 32 |
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial
|
Amaria, Rodabe N
|
|
2018
|
19 |
2 |
p. 181-193
|
artikel
|
| 33 |
Neoadjuvant therapy in melanoma: the next step?
|
Ascierto, Paolo A
|
|
2018
|
19 |
2 |
p. 151-153
|
artikel
|
| 34 |
Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study
|
Gianni, Luca
|
|
2018
|
19 |
2 |
p. 249-256
|
artikel
|
| 35 |
Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial
|
Chi, Kim N
|
|
2018
|
19 |
2 |
p. 194-206
|
artikel
|
| 36 |
Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis
|
Beaver, Julia A
|
|
2018
|
19 |
2 |
p. 229-239
|
artikel
|
| 37 |
PEGPH20 for metastatic pancreatic ductal adenocarcinoma
|
Gourd, Elizabeth
|
|
2018
|
19 |
2 |
p. e81
|
artikel
|
| 38 |
Population-based cancer screening programmes in low-income and middle-income countries: regional consultation of the International Cancer Screening Network in India
|
Sivaram, Sudha
|
|
2018
|
19 |
2 |
p. e113-e122
|
artikel
|
| 39 |
Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study
|
Lee, Jung-Min
|
|
2018
|
19 |
2 |
p. 207-215
|
artikel
|
| 40 |
Revisiting RECIST: the case of treatment beyond progression
|
Daud, Adil I
|
|
2018
|
19 |
2 |
p. 157-159
|
artikel
|
| 41 |
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study
|
DiNardo, Courtney D
|
|
2018
|
19 |
2 |
p. 216-228
|
artikel
|
| 42 |
Salvage regimens for Hodgkin's lymphoma in the brentuximab vedotin era
|
Vitolo, Umberto
|
|
2018
|
19 |
2 |
p. 162-163
|
artikel
|
| 43 |
Smoking cessation medications ineffective in US smokers
|
Das, Manjulika
|
|
2018
|
19 |
2 |
p. e83
|
artikel
|
| 44 |
Tackling cancer burden in low-income and middle-income countries: Morocco as an exemplar
|
Selmouni, Farida
|
|
2018
|
19 |
2 |
p. e93-e101
|
artikel
|
| 45 |
The Study of Letrozole Extension (SOLE) revisited
|
Jordan, V Craig
|
|
2018
|
19 |
2 |
p. e77
|
artikel
|
| 46 |
Use of olaparib in patients with advanced gastric cancer
|
Mo, Miao
|
|
2018
|
19 |
2 |
p. e75
|
artikel
|
| 47 |
Use of olaparib in patients with advanced gastric cancer – Authors' reply
|
Bang, Yung-Jue
|
|
2018
|
19 |
2 |
p. e76
|
artikel
|
| 48 |
Young adults: a unique group in cancer epidemiological research
|
Husson, Olga
|
|
2018
|
19 |
2 |
p. e72
|
artikel
|
| 49 |
Young adults: a unique group in cancer epidemiological research – Authors' reply
|
Fidler, Miranda M
|
|
2018
|
19 |
2 |
p. e73
|
artikel
|
Tijdschrift beschrijving